Header Logo

Connection

MALCOLM BRENNER to Antibodies, Monoclonal

Back to Details
This is a "connection" page, showing publications MALCOLM BRENNER has written about Antibodies, Monoclonal.
MALCOLM BRENNER
Connection Strength
2.191
Antibodies, Monoclonal
  1. Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity. Mol Ther. 2021 05 05; 29(5):1808-1820.
    View in: PubMed
    Score: 0.480
  2. Cellular immunotherapy for neuroblastoma: a review of current vaccine and adoptive T cell therapeutics. Curr Pharm Des. 2009; 15(4):424-9.
    View in: PubMed
    Score: 0.207
  3. CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors. Bone Marrow Transplant. 2005 Jun; 35(12):1127-32.
    View in: PubMed
    Score: 0.162
  4. Complement-fixing CD45 monoclonal antibodies to facilitate stem cell transplantation in mouse and man. Ann N Y Acad Sci. 2003 May; 996:80-8.
    View in: PubMed
    Score: 0.140
  5. Anti-CD45-mediated cytoreduction to facilitate allogeneic stem cell transplantation. Blood. 2003 Mar 15; 101(6):2434-9.
    View in: PubMed
    Score: 0.136
  6. Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. Cancer Res. 2017 04 15; 77(8):2040-2051.
    View in: PubMed
    Score: 0.091
  7. Improving the safety of T-Cell therapies using an inducible caspase-9 gene. Exp Hematol. 2016 Nov; 44(11):1013-1019.
    View in: PubMed
    Score: 0.088
  8. CAR-T Cell Therapy for Lymphoma. Annu Rev Med. 2016; 67:165-83.
    View in: PubMed
    Score: 0.082
  9. Effects of anti-TNF monoclonal antibody infusion in patients with hairy cell leukaemia. Br J Haematol. 1992 Jun; 81(2):231-4.
    View in: PubMed
    Score: 0.066
  10. Enhancement of monoclonal antibody dependent cell mediated cytotoxicity by IL2 and GM-CSF. Br J Haematol. 1989 Dec; 73(4):468-74.
    View in: PubMed
    Score: 0.055
  11. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet. 2009 Sep 12; 374(9693):912-20.
    View in: PubMed
    Score: 0.054
  12. Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1245-52.
    View in: PubMed
    Score: 0.051
  13. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1298-304.
    View in: PubMed
    Score: 0.051
  14. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 2009 Mar 12; 113(11):2442-50.
    View in: PubMed
    Score: 0.051
  15. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun; 39(11):705-9.
    View in: PubMed
    Score: 0.046
  16. CD45 monoclonal antibody-mediated cytolysis of human NK and T lymphoma cells. Haematologica. 2006 Jul; 91(7):886-94.
    View in: PubMed
    Score: 0.044
  17. The use of monoclonal antibodies in graft versus host disease prevention. Haematologia (Budap). 1986; 19(3):167-76.
    View in: PubMed
    Score: 0.042
  18. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab. Bone Marrow Transplant. 2005 Nov; 36(9):797-802.
    View in: PubMed
    Score: 0.042
  19. Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes. Blood. 2005 Mar 15; 105(6):2436-42.
    View in: PubMed
    Score: 0.039
  20. Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy. Biol Blood Marrow Transplant. 2003 Apr; 9(4):273-81.
    View in: PubMed
    Score: 0.035
  21. Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. Cancer Gene Ther. 2001 May; 8(5):378-87.
    View in: PubMed
    Score: 0.030
  22. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000 Feb 15; 95(4):1502-5.
    View in: PubMed
    Score: 0.028
  23. Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1. Lancet. 1995 Sep 23; 346(8978):805-6.
    View in: PubMed
    Score: 0.021
  24. Immunomodulatory effects of human neuroblastoma cells transduced with a retroviral vector encoding interleukin-2. Cancer Gene Ther. 1994 Dec; 1(4):253-8.
    View in: PubMed
    Score: 0.020
  25. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. Bone Marrow Transplant. 1994 May; 13(5):571-5.
    View in: PubMed
    Score: 0.019
  26. Bone marrow transplant recipients have defective MHC-unrestricted cytotoxic responses against cytomegalovirus in comparison with Epstein-Barr virus: the importance of target cell expression of lymphocyte function-associated antigen 1 (LFA1). Blood. 1992 Jun 01; 79(11):3059-66.
    View in: PubMed
    Score: 0.016
  27. IL2 activated killer cells may contribute to cytomegalovirus induced marrow hypoplasia after bone marrow transplantation. Bone Marrow Transplant. 1991 Feb; 7(2):81-7.
    View in: PubMed
    Score: 0.015
  28. Tumor necrosis factor mediates autocrine growth inhibition in a chronic leukemia. J Immunol. 1989 Dec 01; 143(11):3828-34.
    View in: PubMed
    Score: 0.014
  29. Autologous bone marrow transplantation with monoclonal antibody purged marrow for high risk acute lymphoblastic leukemia. Leukemia. 1989 Sep; 3(9):631-6.
    View in: PubMed
    Score: 0.014
  30. Current role and status of bone marrow transplantation. Br J Hosp Med. 1989 Mar; 41(3):260-5.
    View in: PubMed
    Score: 0.013
  31. Differential recovery of phenotypically and functionally distinct circulating antigen-presenting cells after allogeneic marrow transplantation. Transplantation. 1988 Jun; 45(6):1084-91.
    View in: PubMed
    Score: 0.012
  32. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant. 2006 Dec; 12(12):1277-84.
    View in: PubMed
    Score: 0.011
  33. T cell V-gene usage in man in some normal and abnormal situations. Ann N Y Acad Sci. 1991 Dec 30; 636:9-19.
    View in: PubMed
    Score: 0.004
  34. Failure of purged autologous bone marrow transplantation in high risk acute lymphoblastic leukaemia in first complete remission. Bone Marrow Transplant. 1991 Jul; 8(1):19-26.
    View in: PubMed
    Score: 0.004
  35. T cell depleted bone marrow transplantation in acute myeloblastic leukaemia: the way ahead. Bone Marrow Transplant. 1989 Jan; 4 Suppl 1:225-8.
    View in: PubMed
    Score: 0.003
  36. Differential expression of MHC class II antigens in chronic B-cell disorders. Clin Exp Immunol. 1988 Feb; 71(2):217-23.
    View in: PubMed
    Score: 0.003
  37. Standardization of T-cell depletion in HLA matched bone marrow transplantation. Br J Haematol. 1986 Sep; 64(1):69-75.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.